A Study of Asacol Absorption, Metabolism and Excretion in Children and Adolescents With Ulcerative Colitis.
Status:
Terminated
Trial end date:
2008-06-01
Target enrollment:
Participant gender:
Summary
The purpose of this randomized, open-label, parallel-group study is to determine how the body
absorbs and eliminates mesalamine following administration of either 30 mg/kg/day, 60
mg/kg/day or 90 mg/kg/day as 400 mg delayed-release tablets given every 12 hours of 28 days
to children and adolescents with active ulcerative colitis.